Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

darolutamide 4enzalutamide 2apalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Non-metastatic Castration-resistant Prostate Cancer × Clear all
NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06334120 2026-05-13

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Bayer

Recruiting
600 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06013475 2025-06-12

DEAR-EXT

Bayer

Completed
1,375 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT05362149 2024-03-20

DEAR

Bayer

Completed
870 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡